From classified Soviet labs to global longevity clinics
In the early 1970s, the Soviet military gave Vladimir Khavinson, a colonel in the KGB medical corps, a specific mandate: find ways to protect military personnel, cosmonauts, and athletes from the physiological stresses of modern warfare, space travel, and high-performance sport — particularly radiation exposure and rapid ageing under extreme conditions. Working at the St. Petersburg Institute of Bioregulation and Gerontology, Khavinson and his team discovered that short-chain peptides extracted from specific animal organs had remarkable tissue-specific regenerative effects. This research was classified for decades.
The core insight was that every organ produces short regulatory peptides — 2-4 amino acids long — that regulate gene expression in that specific tissue. These "bioregulators" interact directly with DNA through complementary binding, activating genes whose expression has been suppressed by ageing, stress, or disease. The mechanism is epigenetic: not genetic modification, but the restoration of gene expression patterns that decline with age.
After the Soviet Union's collapse in 1991, the research was declassified. Khavinson continued publishing until his death in 2024, accumulating 775 scientific publications and 196 patents. Six peptide-based pharmaceuticals and 64 food supplements were introduced into Russian clinical practice. The research claimed mortality reductions of up to four-fold in human subjects treated with bioregulator protocols — claims that remain extraordinary and require independent replication but are backed by decades of institutionally-conducted research.
The complete family: Cartalax (joints — already in this book), Thymulin (immune/thymus — already in this book), Pinealon (brain/pineal — already in this book), Epitalon (longevity/pineal — already in this book), and Cortagen (brain/cortex) are covered separately. This entry focuses on the organ-specific cardiovascular, hepatic, pulmonary, and metabolic bioregulators.
Gene expression regulation — the DNA interaction model
Shared Mechanism: Khavinson's Model
The organ-specific family
Cardiogen (Ala-Glu-Asp · P6): Cardiac tissue bioregulator. Targets gene expression in cardiomyocytes to support contractile function, reduce oxidative damage, and promote cellular repair. Clinical trial data in Russia shows reduced ischaemic heart disease incidence in treated patients vs controls.
Bronchogen (Ala-Asp-Glu-Leu): Lung and bronchial bioregulator. The Monaselidze study showed Bronchogen affects DNA thermostability — suggesting direct chromatin/gene interaction. Used for pulmonary support and respiratory tissue protection.
Livagen (Lys-Glu-Asp-Ala): Liver bioregulator with demonstrated chromatin remodelling effects. Timofeeva et al. showed Livagen affects digestive enzyme activity in rats across different ages. Khavinson's landmark study showed Livagen reactivated chromatin in lymphocytes from elderly subjects — one of the most compelling direct demonstrations of the epigenetic bioregulator mechanism.
Ovagen (Glu-Asp-Leu): Liver and stomach bioregulator. Pancragen (Lys-Glu-Asp): pancreatic bioregulator for insulin secretion and pancreatic tissue support. Prostamax (Lys-Glu-Asp-Ala): prostate gland bioregulator. Chonluten (Gly-Glu-Pro): bronchial/respiratory mucosal support.
Evidence caveat: The vast majority of Khavinson bioregulator research originates from the St. Petersburg Institute of Bioregulation and Gerontology — a single institution. Independent replication by Western research groups is limited. The claims are bold, the publications are numerous, and the mechanism is theoretically plausible — but the gold standard of independent multi-centre RCTs does not exist for most of these peptides outside Russia.